Home › Trial NCT03674567
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
- Trial IDNCT03674567
- StatusCompleted
- PhasePhase 1/2
- Study typeInterventional
- SponsorRAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Enrollment323
- Start date2018-09-25
- ConditionsAdvanced Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.